

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On JULY 3, 2006

TOWNSEND and TOWNSEND and CREW LLP



Humbly Kara

PATENT
Attorney Docket No.: 015280-361200US
Client Reference No.: E-058-1998/0-US-05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FITZGERALD et al.

Application No.: 10/659,036

Filed: September 9, 2003

For: PSEUDOMONAS EXOTOXIN A-
LIKE CHIMERIC IMMUNOGENS FOR
ELICITING A SECRETORY IGA-
MEDIATED IMMUNE RESPONSE

Confirmation No.: 3296

Examiner: Agnieszka Boesen

Art Unit: 1648

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on the attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references, numbers 51, 59, 60, 63, 69, 70, 75, 76, 82, 84, 86, 87, 88, 91-93, 96, 97, 99, 100, 106, 108, 109, 113, 119, 120, 125, 126, 134, 137, 138, 141, 146, 152, 155, and 156, can be found in Application No. 09/462,713, filed May 12, 2000 (Attorney Docket No. 015280-361200US). Copies of all other references [in compliance with the requirements of 37 CFR §1.98(a)(2)] are enclosed herewith. It is respectfully requested that the cited references be expressly considered

during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
FJM:jvl
60802454 v1



PTO/SB/08A (07-05)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/659,036		
		Filing Date	September 9, 2003		
		First Named Inventor	FitzGerald, David J.		
		Art Unit	1648		
		Examiner Name	Agnieszka Boesen		
Sheet	1	of	12	Attorney Docket Number	015280-361200US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	4,545,985	10-08-1985	Pastan et al.	
	2.	4,892,827	01-09-1990	Pastan et al.	
	3.	4,958,009	09-19-1990	Bjorn et al.	
	4.	5,082,927	01-21-1992	Pastan et al.	
	5.	5,190,873	03-02-1993	Lernhardt et al.	
	6.	5,206,353	04-27-1993	Berger et al.	
	7.	5,328,984	07-12-1994	Pastan et al.	
	8.	5,428,143	06-27-1995	Berger et al.	
	9.	5,458,878	10-17-1995	Pastan et al.	
	10.	5,512,658	04-30-1996	Pastan et al.	
	11.	5,573,916 A	11-12-1996	Cheronis et al.	
	12.	5,587,455	12-24-1996	Berger et al.	
	13.	5,602,095	02-11-1997	Pastan et al.	
	14.	5,608,039	03-04-1997	Pastan et al.	
	15.	5,612,036	03-18-1997	Hodges et al.	
	16.	5,696,237	12-09-1997	FitzGerald et al.	
	17.	5,705,156	01-06-1998	Pastan et al.	
	18.	5,705,163	01-06-1998	Pastan et al.	
	19.	5,821,238	12-13-1998	Pastan et al.	
	20.	5,843,882	12-01-1998	Boyd et al.	
	21.	5,854,044	12-29-1998	Pastan et al.	
	22.	5,863,745	01-26-1999	FitzGerald et al.	
	23.	5,869,045	02-09-1999	Hellstrom et al.	
	24.	5,935,580	08-10-1999	Ladant et al.	
	25.	5,965,406 A	10-12-1999	Murphy	
	26.	5,980,895	11-09-1999	Pastan et al.	
	27.	5,980,896	11-09-1999	Hellstrom et al.	
	28.	5,990,296	11-23-1999	Pastan et al.	
	29.	6,011,002 A	01-04-2000	Pastan et al.	
	30.	6,020,145	02-01-2000	Hellstrom et al.	
	31.	6,022,950 A	02-08-2000	Murphy	
	32.	6,051,405	04-18-2000	Fitzgerald et al.	
	33.	6,074,644	06-13-2000	Pastan et al.	
	34.	6,083,502	07-04-2000	Pastan et al.	
	35.	6,086,900	06-11-2000	Draper	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60802454 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/659,036	
			Filing Date	September 9, 2003	
			First Named Inventor	FitzGerald, David J.	
			Art Unit	1648	
			Examiner Name	Agnieszka Boesen	
Sheet	2	of	12	Attorney Docket Number	015280-361200US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	36.	6,090,388	07-18-2000	Wang	
	37.	6,099,842	08-08-2000	Pastan et al.	
	38.	6,140,066	10-31-2000	Lorberbaum-Galski et al.	
	39.	6,146,631	11-14-2000	Better et al.	
	40.	6,303,120	10-16-2001	Danishefsky et al.	
	41.	6,423,513 B1	06-23-2002	Fitzgerald et al.	
	42.	6,426,075 B1	07-30-2002	Fitzgerald et al.	
	43.	6,498,233 B1	12-24-2002	Wels et al.	
	44.	6,531,133 B1	03-11-2003	Lorberbaum-Galski et al.	
	45.	6,783,761	08-31-2004	Grimes et al.	
	46.	6,881,718	04-19-2005	Fitzgerald et al.	
	47.	2002/0106370	08-08-2002	Cardy et al.	
	48.	2004/0247617	12-09-2004	Liao et al.	
	49.	2005/0079171	04-14-2005	Fitzgerald et al.	
	50.	SN 09/462,682	01-10-2000	FitzGerald	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	51.	EP	0 439 954	A2	08-07-1991	Seragen, Inc.		<input type="checkbox"/>
	52.	EP	0 583 794	B1	09-23-1987	Pastan et al.		<input type="checkbox"/>
	53.	WO	86/06635	A1	11-20-1986	Biotech Australia Pty Ltd.		<input type="checkbox"/>
	54.	WO	90/13563	A	11-15-1990	Univ Alberta		<input type="checkbox"/>
	55.	WO	93/11791	A	06-14-1993	Oregon State		<input type="checkbox"/>
	56.	WO	95/07297	A1	03-16-1995	Menarini Ricerche Sud		<input type="checkbox"/>
	57.	WO	95/31483	A	11-23-1995	Cardy et al.		<input type="checkbox"/>
	58.	WO	97/13529	A1	04-17-1997	Gov't of USA		<input type="checkbox"/>
	59.	WO	97/15529	A	04-17-1997	Pastan et al.		<input type="checkbox"/>
	60.	WO	98/20135	A	05-14-1998	U.S. Govt.		<input type="checkbox"/>
	61.	WO	98/42876	A1	10-01-1998	Univ. Texas		<input type="checkbox"/>
	62.	WO	99/02712	A1	01-21-1999	Gov't of USA		<input type="checkbox"/>
	63.	WO	99/02713	A	01-21-1999	FitzGerald		<input type="checkbox"/>
	64.	WO	99/57142	A	11-11-1999	Univ Alberta		<input type="checkbox"/>
	65.	WO	00/46246	A1	08-10-2000	Gen Hospital Corp.		<input type="checkbox"/>
Examiner Signature					Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60802454 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	3	of	12	Attorney Docket Number	015280-361200US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	66.	WO	01/30392	A2	05-03-2001	U.S. Govt. & Genentech		<input type="checkbox"/>
	67.	WO	01/31020	A1	05-03-2001	U.S. Govt.		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60802454 v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
Examiner Name	Agnieszka Boesen				
Attorney Docket Number	015280-361200US				
Sheet	4	of	12		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	68.	ANDREASEN, P.A. et al., "Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes." FEBS Letters, Vol. 338, No. 3; pp. 239-45 (1994)	<input type="checkbox"/>
	69.	ASHORN, P. et al., "Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors," Proc. Natl. Acad. Sci. USA., 87:8889-8893 (1990).	<input type="checkbox"/>
	70.	BACKSTROM, M. et al., "Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit," Gene, 149:211-217 (1994)	<input type="checkbox"/>
	71.	BATRA, J.K. et al., "Single-chain immunotoxins directed at the human transferring receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)" Mol. Cell. Biol.; Vol. 11, No. 4; pp. 2200-2205 (Apr. 1991) [Abstract only]	<input type="checkbox"/>
	72.	BENHAR, I. et al., "Pseudomonas Exotoxin A Mutants: Replacement of surface-exposed residues in domain III with cysteine residues that can be modified with polyethylene glycol in a site-specific manner" J. Biol. Chem. 269(18):13398-13404 (1994)	<input type="checkbox"/>
	73.	BERAUD, E. et al.: "Immunospecific suppression of encephalitogenic-activated T lymphocytes by chimeric cytotoxin IL-2-PE40" Cell. Immunol.; Vol. 133, No. 2; pp. 379-389 (Apr. 1991) [Abstract only]	<input type="checkbox"/>
	74.	BERGER, E. et al., "CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses" PNAS USA 86:9539-9543 (1989)	<input type="checkbox"/>
	75.	BERMAN, P.W. et al., "Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160," Nature, 345:622-625 (1990)	<input type="checkbox"/>
	76.	BRINKMANN et al., "Immunotoxins against cancer," Biochimica et Biophysica Acta, 1198:27-45 (1994)	<input type="checkbox"/>
	77.	BRINKMANN, U. et al., "Alteration of a protease-sensitive region of Pseudomonas exotoxin prolongs its survival in the circulation of mice" PNAS USA 89:3065-3069 (1992)	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	5	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	78.	BRINKMANN, U. et al., "Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins: Influence of interdomain connections" PNAS USA 89:3075-3079 (1992)	<input type="checkbox"/>	
	79.	CATASTI, P. et al., "Local and global structural properties of the HIV-MN V3 loop," J. Biol. Chem. 270(5):2224-32 (1995)	<input type="checkbox"/>	
	80.	CAVALLARO, U. et al., "Targeting plant toxins to the urokinase and α -2-macroglobulin receptors." Semin. Cancer Biol., Vol. 6, No. 5; pp. 269-78 (1995)	<input type="checkbox"/>	
	81.	CHAUDHARY, V. et al., "Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity" J. Biol. Chem. 265(27):16303-16310 (1990)	<input type="checkbox"/>	
	82.	CHAUDHARY, V. et al., "Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity," PNAS, USA 87(1):308-12 (1990)	<input type="checkbox"/>	
	83.	CHAUDHARY, V. et al., "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein" Nature 335:369-372 (1988)	<input type="checkbox"/>	
	84.	CHAUDHARY, V., et al., "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," Nature 33:369-372.	<input type="checkbox"/>	
	85.	CHOE, M. et al., "B3(Fab)-PE38M: A recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3" Cancer Res. 54:3460-3467 (1994)	<input type="checkbox"/>	
	86.	CRYZ, S.J. et al., "Human immunodeficiencyvirus-1 principal neutralizing domain peptide-toxin A conjugate vaccine" Vaccine 13(1):67-71 (1995)	<input type="checkbox"/>	
	87.	CRYZ, S.J. et al., "Safety and Immunogenicity of a Pseudomonas aeruginosa O-Polysaccharide Toxin A Conjugate Vaccine in Humans," J. Clin. Invest., 80:51-56 (1987)	<input type="checkbox"/>	
	88.	CRYZ, S.J. et al., "Safety and Immunogenicity of Escherichia coli O18 O-Specific Polysaccharide (O-PS)-Toxin and O-PS-Cholera Toxin Conjugate Vaccines in Humans," J. Infectious Diseases, 163:1040-1045 (1990)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	6	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	89.	DAUGHERTY, A.L. et al., "Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node." J. Controlled Release, Vol. 65, Nos. 1-2; pp. 297-302 (2000)	<input type="checkbox"/>	
	90.	DEBINSKI, W. and I. PASTAN: "Recombinant F(ab') C242-Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a colorectal tumor xenograft" Clin. Cancer Res.; Vol. 1; pp. 1015-1022 (Sept. 1995)	<input type="checkbox"/>	
	91.	EATON, A.M. et al., "An Anti-gp41 Human Monoclonal Antibody That Enhances HIV-1 Infection in the Absence of Complement," Aids Res. Hum. Retroviruses, 10:13-18(1994)	<input type="checkbox"/>	
	92.	EMINI, E.A. et al., "Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody," Nature, 355:728-730 (1992)	<input type="checkbox"/>	
	93.	EVANS, D.J. et al., "An engineered poliovirus chimera elicits broadly reactive HIV-1 neutralizing antibodies," Nature, 339:385-388 (1989)	<input type="checkbox"/>	
	94.	FATTOM, A. et al., "Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-Succinimidyl-3-(2-pyridyldithio)propionate" Infection and Immunity 60(2):584-589 (1992)	<input type="checkbox"/>	
	95.	FATTOM, A. et al., "Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A" Infection and Immunity 61(3):1023-1032 (1993)	<input type="checkbox"/>	
	96.	FITZGERALD, D.J. et al., "Characterization of V3 loop-pseudomonas exotoxin chimeras," J. Biol. Chem. 273(16):9951-58 (1998)	<input type="checkbox"/>	
	97.	FONTENOT, J.D. et al., "Human immunodeficiency virus (HIV) antigens: Structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins," Proc. Natl. Acad. Sci. USA, 92:315-319 (1995)	<input type="checkbox"/>	
	98.	GAWLAK, S.L. et al.: "Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin" Bioconjug. Chem.; Vol. 4, No. 6; pp. 483-489 [Abstract only]	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	7	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	99.	GORSE et al., "Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine," Clinical and Diagnostic Lab. Immun. 3(6):769-773 (1996)	<input type="checkbox"/>	
	100.	GRANT, G., "Synthetic peptides: A User's Guide/ Edited by Gregory A. Grant," Freeman, pps. 9, 63-67, 72 (1992).	<input type="checkbox"/>	
	101.	HAHN, H. et al., "Pilin-based anti-Pseudomonas vaccines: latest developments and perspectives," Behring Institute 98:315-25 (1997)	<input type="checkbox"/>	
	102.	HELMBROOK, D.C. et al.: "Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts" Proc. Natl. Acad. Sci. USA; Vol. 87, No. 12; pp. 4697-4701 (Jun. 1990) [Abstract only]	<input type="checkbox"/>	
	103.	HERTLE, R. et al., "Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein," Inf. Immun. 69(11):6962-69 (2001)	<input type="checkbox"/>	
	104.	HERZ J. and D.K. STRICKLAND, "LRP: a multifunctional scavenger and signaling receptor." J Clin Invest., Vol. 108, No. 6; pp. 779-84. (2001)	<input type="checkbox"/>	
	105.	HINKULA et al., "Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses," Vaccine 15(8):874-78 (1997)	<input type="checkbox"/>	
	106.	JAVAHERIAN, K. et al., "Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein," Proc. Natl. Acad. Sci. USA, 86:6768-6772 (1989)	<input type="checkbox"/>	
	107.	JINNO, Y. et al., "Domain II mutants of Pseudomonas exotoxin deficient in translocation" J. Biol. Chem. 264(27):15953-15959 (1989)	<input type="checkbox"/>	
	108.	JOHANSEN, H.K. et al., "Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A," APMIS 102(7):545-553 (1994)	<input type="checkbox"/>	
	109.	JOHANSEN, H.K., "Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: experimental studies in animals," APMIS Supplement S63(1):1-42 (1996)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	8	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	110.	JOHNSON, K. et al., "Nucleotide sequence and transcriptional initiation site of two Pseudomonas aeruginosa pilin genes" J. Biol. Chem. 261(33):15703-15708 (1986)	<input type="checkbox"/>	
	111.	KASTURI, S. et al., "Alanine scanning mutagenesis identifies surface amino acids on domain III of Pseudomonas exotoxin required for cytotoxicity, proper folding, and secretion into periplasm" J. Biol. Chem. 267(32):23427-23433 (1992)	<input type="checkbox"/>	
	112.	KONDO, T. et al., "Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain" J. Biol. Chem. 263(19):9470-9475 (1988)	<input type="checkbox"/>	
	113.	KOVACS, J.A. et al., "Induction of Humoral and Cell-mediated Anti-Human Immunodeficiency Virus (HIV Responses in HIV Sero-negative Volunteers by Immunization with Recombinant gp160," J. Clin. Invest., 92:919-928 (1993)	<input type="checkbox"/>	
	114.	KREITMAN, R. et al., "Properties of chimeric toxins with two recognition domains: Interleukin 6 and transforming growth factor α at different locations in Pseudomonas exotoxin" Biocon. Chem 3:63-68 (1992)	<input type="checkbox"/>	
	115.	KREITMAN, R.J. et al., "Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin" Bioconjug. Chem.; Vol. 4, No. 6; pp. 581-585 [Abstract only]	<input type="checkbox"/>	
	116.	KUAN, C. et al., "Improved antitumor activity of a recombinant anti-Lewis y immunotoxin not requiring proteolytic activation" PNAS USA 93:974-978 (1996)	<input type="checkbox"/>	
	117.	KUAN, C. et al., "Pseudomonas exotoxin A mutants: Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner" J. Biol. Chem. 269(10):7610-7616 (1994)	<input type="checkbox"/>	
	118.	KUAN, C.T. et al.: "Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome" Clin. Cancer Res.; Vol. 1, No. 12; pp. 1589-1594 (Dec. 1995) [Abstract only]	<input type="checkbox"/>	
	119.	LEGER et al., "Humanization of a mouse antibody against α -4 integrin: a potential therapeutic for the treatment of multiple sclerosis," Human Antibodies 8:3-16 (1997)	<input type="checkbox"/>	
	120.	LUKAC, M. et al., "Toxoid of Pseudomonas aeruginosa Exotoxin A Generated by Deletion of an Active-Site Residue," Infection and Immunity, 56(12):3095-3098 (1988)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	9	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	121.	MANSFIELD, E. et al., "Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies" Bioconj. Chem. 7:557-563 (1996)	<input type="checkbox"/>	
	122.	MAZIERE, J.C. et al., "Processing and characterization of the low density lipoprotein receptor in the human colonic carcinoma cell subclone HT29-18: a potential pathway for delivering therapeutic drugs and genes." Biosci. Rep., Vol. 12, No. 6; pp. 483-94 (1992)	<input type="checkbox"/>	
	123.	MELMAN, L. et al., "High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs." J. Biol. Chem., Vol. 276, No. 31; pp. 29338-46 (2001)	<input type="checkbox"/>	
	124.	MICKISCH, G.H. et al.: "Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mouse" J. Urol.; Vol. 149, No. 1; pp. 174-178 (Jan. 1993) [Abstract only]	<input type="checkbox"/>	
	125.	MITCHELL, W.M. et al., "Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques," Aids, 9:27-34 (1995)	<input type="checkbox"/>	
	126.	MONTEFIORI, D.C. et al., "Neutralizing and Infection-Enhancing Antibody Responses to Human Immunodeficiency Virus Type 1 in Long-Term Nonprogressors," J. Infect. Dis., 173:60-67 (1996)	<input type="checkbox"/>	
	127.	MOORE et al., "Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells," Vaccine 13(18):1741-49 (1995)	<input type="checkbox"/>	
	128.	MOORE, Chapter 2 in <u>Synthetic Peptides: A User's Guide</u> , W.H. Freeman & Co., N.Y. Chapter 2 pp.63-67	<input type="checkbox"/>	
	129.	MRSNY et al., "Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses," Vaccine 17:1425-33 (1999)	<input type="checkbox"/>	
	130.	OGATA, M. et al., "Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol" J. Biol. Chem. 267(35):25396-25401 (1992)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	10	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	131.	OGATA, M. et al., "Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-da toxin fragment that is translocated to the cytosol" J. Biol. Chem. 265(33):20678-20685 (1990)	<input type="checkbox"/>	
	132.	PAI, L.H. et al.: "Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40)" Cancer Res.; Vol. 51, No. 11; pp. 2808-2812 (Jun. 1991) [Abstract only]	<input type="checkbox"/>	
	133.	PAI, L.H. et al.: "Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin" Nat. Med.; Vol. 2, No. 3; pp. 350-353 (Mar. 1996) [Abstract only]	<input type="checkbox"/>	
	134.	PARR et al., "Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated HSV-2," J. Virology pp.8109-8115 (1997)	<input type="checkbox"/>	
	135.	PASTAN, I. et al., "Pseudomonas exotoxin: chimeric toxins" J. Biol. Chem. 264(26):15157-15160 (1989)	<input type="checkbox"/>	
	136.	PURI, R.K. et al.: "A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes" J. Immunol.; Vol. 152, No. 7; pp. 3693-3700 (Apr. 1994) [Abstract only]	<input type="checkbox"/>	
	137.	QUE, J.U. et al., "Effect of Carrier Selection on Immunogenicity of Protein Conjugate Vaccines against Plasmodium falciparum Circumsporozoites," Infection and Immunity, 56:2645-2649 (1988)	<input type="checkbox"/>	
	138.	REITER et al., "Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments," Nature Biotechnology, 14:1239-1245 (1996)	<input type="checkbox"/>	
	139.	REITER, Y et al.: "Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin" Int. J. Cancer; Vol. 58, No. 1; pp. 142-149 (Jul. 1994) [Abstract only]	<input type="checkbox"/>	
	140.	RUBINSTEIN, A. et al., "Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers," AIDS 9(3):243-51 (1995)	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	11	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	141.	RUSCHE, J.R. et al., "Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120," Proc. Natl. Acad. Sci. USA, 85:3198-3202 (1988)	<input type="checkbox"/>	
	142.	SEETHARAM, S. et al., "Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL" J. Biol. Chem. 266(26):17376-17381 (1991)	<input type="checkbox"/>	
	143.	SIEGALL, C. et al., "Analysis of sequences in domain II of Pseudomonas exotoxin A which mediate translocation" Biochemistry 30:7154-7159 (1991)	<input type="checkbox"/>	
	144.	SIEGALL, C. et al., "Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin" J. Biol. Chem. 264(24):14256-14261 (1989)	<input type="checkbox"/>	
	145.	SIEGALL, C.B. et al.: "In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins" Bioconjug. Chem.; Vol. 5, No. 1; pp. 77-83 [Abstract only]	<input type="checkbox"/>	
	146.	STEIMER, K.S. et al., "Neutralization of Divergent HIV-1 Isolates by Conformation-Dependent Human Antibodies to Gp120," Science, 254:105-108 (1991)	<input type="checkbox"/>	
	147.	SWISS PROT Accession No. P11439, Pseudomonas aeruginosa exotoxin A amino acid sequence entered in October 1989	<input type="checkbox"/>	
	148.	THEUER, C. et al., "A recombinant form of Pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing" J. Biol. Chem. 267(24):16872-16877 (1992)	<input type="checkbox"/>	
	149.	THEUER, C. et al., "Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity" Cancer Res. 53:340-347 (1993)	<input type="checkbox"/>	
	150.	THEUER, C. et al.: "Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes" Biochemistry; Vol. 33, No. 19; pp. 5894-5900 (May 1994) [Abstract only]	<input type="checkbox"/>	
	151.	THEUER, C.P. et al.: "The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion" Proc. Acad. Natl. Sci. USA; Vol. 90, No. 16; pp. 7774-7778 (Aug. 1993) [Abstract only]	<input type="checkbox"/>	
Examiner Signature				Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/659,036
				Filing Date	September 9, 2003
				First Named Inventor	FitzGerald, David J.
				Art Unit	1648
				Examiner Name	Agnieszka Boesen
Sheet	12	of	12	Attorney Docket Number	015280-361200US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	152.	TOTH, F.D. et al., "Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro," Clin. Exp. Immunol., 96:389-394 (1994)	<input type="checkbox"/>	
	153.	VERSLUIS, A.J. et al., "Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo." J. Pharmacol. Experiment. Therap., Vol. 289, No. 1; pp. 1-7 (1999)	<input type="checkbox"/>	
	154.	WALL, D. et al., "Type IV pili and cell motility," Mol. Microbiol. 32(1):1-10 (1999)	<input type="checkbox"/>	
	155.	WANG, C.Y. et al., "Long-Term High-Titer Neutralizing Activity Induced by Octameric Synthetic HIV-1 Antigen," Science, 254:285-288 (1991)	<input type="checkbox"/>	
	156.	WHITE-SCHARF, M.E. et al., "Broadly Neutralizing Monoclonal Antibodies to the V3 Region of HIV-1 Can Be Elicited by Peptide Immunization," Virology, 192:197-206 (1993)	<input type="checkbox"/>	
	157.	ZDANOVSKY, A. et al., "Mechanism of action of Pseudomonas exotoxin" J. Biol. Chem. 268(29):21791-21799 (1993)	<input type="checkbox"/>	
	158.	ZDANOVSKY, A.G. et al., "Targeting pseudomonas and diphtheria toxins to the alpha-2-macroglobulin receptor via RAP-toxin and PAI-I-toxin fusions." Prot. Engin., Vol. 8, No. Suppl., pp. 123 (1995)	<input type="checkbox"/>	
			<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.